Status | Study |
Completed |
Study Name: A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis Condition: Actinic Keratosis Date: 2013-08-12 Interventions: Drug: LEO 43204 Formulation 1 Drug: LEO 43 |
Completed |
Study Name: Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis Condition: Actinic Keratosis Date: 2013-03-25 Interventions: Drug: Ingenol mebutate gel Drug: placebo |
Completed |
Study Name: Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects Condition: Healthy Date: 2013-01-03 Interventions: Drug: Rotigotine transdermal patch Rotigotine transdermal patch, single-dose application over 24 hours 2 |
Recruiting |
Study Name: Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2 Condition: Venous Leg Ulcers Date: 2012-11-20 Interventions: Biological: HP802-247 HP802-24 |
Completed |
Study Name: Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems Condition: Hypogonadism Date: 2011-03-21 Interventions: Drug: testosterone matrix transdermal system |
Completed |
Study Name: Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body Condition: Healthy Volunteers Date: 2010-01-28 Interventions: Drug: Rotigotine transdermal patch Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours |
Terminated |
Study Name: Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment Condition: Multiple Sclerosis Cognitive Impairment Date: 2009-04-14 Interventions: Drug: Rivastigmine transdermal patch |
Completed |
Study Name: Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch Condition: Healthy Date: 2008-11-14 Interventions: Drug: testosterone 28 cm2 test |
Completed |
Study Name: Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. Condition: Alzheimer's Disease Date: 2008-08-05 Interventions: Drug: Rivastigmine transdermal patch |
Completed |
Study Name: Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2 Condition: Actinic Keratosis Date: 2008-04-15 Interventions: Drug: PEP005 Topical gel 0.05%, two day dose |